



CCS Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.		
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit
Primary Panel			
Satish R. Raj	Allergan, Lundbeck LLC, GE Healthcare	Bristol-Myers Squibb, Medtronic	None
Juan Camilo Guzman	None	None	None
Paula Harvey	None	None	None
Lawrence Richer	None	Janssen	None
Ronald Schondorf	None	None	None
Colette Seifer	None	None	None
Robert S. Sheldon	None	None	None
Secondary Panel and International Members			
Hoshiar Abdollah	None	None	None
Carlos A. Morillo	Abbott Canada, Bayer, Boston Scientific, Daiichi-Sankyo, Medtronic, Merck, Pfizer, St. Jude Medical, Biotronik	Bayer, Boston Scientific, Daiichi-Sankyo, Medtronic, Servier	None
Shubhayan Sanatani	Audentes	None	None
Tara Sedlak	Amgen, Boehringer Ingelheim / Eli Lilly Alliance, Sanofi	None	None
Zaeem A. Siddiqi	None	GlaxoSmithKline, Pfizer	None
David Cannom			
Nicholas Gall	None	None	Medtronic
Julia Newton	None	None	None
Win Shen			